Press Releases April 7, 2026 08:00 AM

Recursion to Participate in Upcoming Investor Conferences

Recursion Announces Participation in Key Investor Conferences to Showcase its TechBio Innovations

By Caleb Monroe RXRX
Recursion to Participate in Upcoming Investor Conferences
RXRX

Recursion (Nasdaq: RXRX), a clinical-stage TechBio company specializing in AI-driven drug discovery, announced its participation in the 25th Annual Needham Virtual Healthcare Conference and the Bank of America Health Care Conference in 2026. The company highlights its AI-native platform, Recursion OS, which integrates biology, chemistry, and clinical development to accelerate medicinal advancements in various therapeutic areas. These investor events aim to provide updates on Recursion's pipeline and platform progress.

Key Points

  • Recursion will present at two major healthcare investor conferences in April and May 2026.
  • The company emphasizes its AI-native Recursion OS platform for drug discovery across oncology, rare diseases, neuroscience, and immunology.
  • Recursion's operations span automated biology and chemistry labs in Utah and Oxfordshire, with additional offices in major global innovation hubs.
  • The announcement impacts the biotech and healthcare sectors, especially the intersection of AI and drug development.

Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences:

  • 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026
  • Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026

Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.
About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.


Risks

  • Clinical-stage pipeline carries typical risks of drug development including regulatory approval uncertainties.
  • The effectiveness and competitive positioning of Recursion's AI platform remain critical to commercial success.
  • Market adoption and integration of new AI-driven technologies in drug discovery may face operational and collaboration challenges.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026